News
ASRT
1.505
+2.38%
0.035
Assertio Holdings Price Target Announced at $3.00/Share by Maxim Group
Dow Jones · 9h ago
Assertio Holdings Initiated at Buy by Maxim Group
Dow Jones · 9h ago
ASSERTIO HOLDINGS INC <ASRT.O>: MAXIM GROUP INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $3
Reuters · 14h ago
U.S. RESEARCH ROUNDUP-Alexander & Baldwin, Instructure Holdings, RPM International
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Alexander & Baldwin, Instructure Holdings, RPM International and UnitedHealth Group among companies. American Airlines, Apple and Abbvie among companies with revised targets. The analysts also raised their ratings on several other companies.
Reuters · 19h ago
Assertio shareholder calls for four board members to resign
Healthcare Assertio shareholder calls for four board members to resign. Buxton Helmsley Group has "grave concerns" about the company's handling of its acquisition of Spectrum Pharmaceuticals. The company's shares are down 72% over the last year. AssertIO Holdings has a 1% stake in the company.
Seeking Alpha · 2d ago
Buxton Helmsley Issues Letter To Assertio Holdings, Inc; Calls For The Immediate Resignation Of Four Directors, Including Chairman Peter Staple, Heather Mason, William Mckee And Dr. Jeffrey Vacirca
A significant shareholder of Assertio Holdings, Inc. Calls for the resignation of four of the company's directors. The Buxton Helmsley Group says the board failed to explain the value-destructive Spectrum Pharmaceuticals acquisition. The group also wants the company to improve its due diligence process.
Benzinga · 2d ago
Weekly Report: what happened at ASRT last week (0715-0719)?
Weekly Report · 4d ago
Offerpad Solutions: Now Is The Time To Go Against The Crowd
Seeking Alpha · 5d ago
Weekly Report: what happened at ASRT last week (0708-0712)?
Weekly Report · 07/15 11:04
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
NASDAQ · 07/10 09:58
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Assertio Holdings, Inc. Granted four newly-hired employees a total of 44,575 restricted stock units and 142,910 stock options effective July 1, 2024. The company is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients.
Barchart · 07/09 15:30
Weekly Report: what happened at ASRT last week (0701-0705)?
Weekly Report · 07/08 11:06
H.C. Wainwright starts Assertio at buy, calls stock underrated, overlooked
Seeking Alpha · 07/03 19:45
Assertio Holdings Price Target Announced at $4.00/Share by HC Wainwright & Co.
Dow Jones · 07/03 10:26
Assertio Holdings Initiated at Buy by HC Wainwright & Co.
Dow Jones · 07/03 10:26
HC Wainwright & Co. Initiates Coverage On Assertio Holdings with Buy Rating, Announces Price Target of $4
Benzinga · 07/03 10:15
ASSERTIO HOLDINGS, INC. <ASRT.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $4
Reuters · 07/03 10:04
U.S. RESEARCH ROUNDUP-Ardelyx, Eli Lilly, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Ardelyx, Eli Lilly, Tesla and Waste Management among companies with revised targets. Analysts cut their ratings on several companies on Wednesday. Some analysts raised their targets on some of the companies.
Reuters · 07/03 07:08
Weekly Report: what happened at ASRT last week (0624-0628)?
Weekly Report · 07/01 11:06
Assertio: An Extremely Asymmetric Bet Skewed To The Upside
Assertio Holdings, Inc. Shares present a significant upside potential due to ongoing turnaround efforts. The merger with Spectrum Pharmaceuticals saved Assertio from potential collapse after a generic drug approval. The company is an expert in monetizing underappreciated pharma assets. A DCF valuation model suggests a fair equity value of $4.00 per share.
Seeking Alpha · 06/27 13:51
More
Webull provides a variety of real-time ASRT stock news. You can receive the latest news about Assertio Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ASRT
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).